Are Peptides Legal in Montana? (2026)

The federal rules that apply in Montana, as everywhere

Federal law is the same in every state, and it is where almost all of the legal weight sits. Under the Federal Food, Drug, and Cosmetic Act a product intended to treat a condition or change how the body works is a drug, and an unapproved new drug cannot be introduced into interstate commerce. That rule binds the seller, not the buyer. The FDA's 2026 warning letters to research-peptide vendors say the same thing eleven times over: a "research use only" label does not help when the website, the bundled bacteriostatic water or a dosing calculator shows the product is meant for human use. The Bureau's enforcement tracker lists every letter, case and lawsuit with its source.

Three federal points matter for a reader in Montana:

• Human growth hormone is the exception. 21 U.S.C. § 333(e) makes it a federal offence to distribute or possess somatropin for any use not approved by the Secretary of HHS. That statute covers HGH itself, not the secretagogues (sermorelin, ipamorelin, CJC-1295) that prompt the body's own release.
• Compounding is a separate track. A licensed pharmacy may only compound from bulk substances on the FDA's 503A list. BPC-157, TB-500, MOTS-c, KPV, Semax and Epitalon were moved to Category 2 in September 2023, removed from it in April 2026, and recommended for the list by the FDA's advisory committee on 23 and 24 July 2026. No rule has followed as of September 2026, so they still cannot be legally compounded anywhere, including Montana. The PCAC vote page has every tally.
• GLP-1 compounding is closing, not opening. The FDA has declared the semaglutide and tirzepatide shortages over, proposed in April 2026 to keep both off the 503B bulks list, and sent batches of letters to telehealth sellers in March and June 2026. Vials sold as "GLP-1 S" or "GLP-3 R" for research are unapproved new drugs in the FDA's view wherever the buyer lives.

What Montana law adds

Montana's controlled-substances law (Mont. Code Ann. Title 50, chapter 32 (Controlled Substances), Part 2; Schedule III at MCA § 50-32-226) decides whether possessing a compound is a state offence. Peptides only become a state-law problem if they appear in those schedules or in a specific state ban. (mca.legmt.gov)

The Bureau found no research peptide (BPC-157, TB-500, ipamorelin, sermorelin, semaglutide, tirzepatide, retatrutide or the others covered on this site) on Montana's schedules or in a Montana-specific ban as of September 2026. That is the position in most states.

Human growth hormone

Montana's Schedule III covers anabolic steroids but does not list human growth hormone, somatropin or chorionic gonadotropin, so only the federal HGH statute applies. (MCA § 50-32-226) (mca.legmt.gov)

Compounded semaglutide and tirzepatide

No Montana Board of Pharmacy statement specific to compounded GLP-1 drugs was located. Licensed Montana pharmacies follow the federal 503A and 503B rules, under which the shortage exception for semaglutide and tirzepatide has ended.

Clinics, medspas and prescribers

No Montana medical board guidance specific to peptide therapy was located. A Montana prescriber who administers BPC-157 or another unapproved peptide is exposed under the state's medical practice act and, since the FDA's 2026 letters, under federal law; the July 2026 advisory vote has not changed that yet.

Buying, possessing and using research peptides in Montana

MCA § 45-9-102 (criminal possession of dangerous drugs) reaches only scheduled substances, so an individual possessing an unscheduled research peptide commits no Montana drug offence; the federal rules bind the sellers. (mca.legmt.gov)

Ordering from a vendor in another state. Almost every research-peptide order into Montana is interstate commerce, which is exactly what the FDCA governs. The risk sits with the vendor: the FDA's letters name the seller, and Eli Lilly said in August 2026 it had referred more than 200 sellers to the FDA, the DOJ, state attorneys general and licensing boards. Connecticut's attorney general has already used state consumer-protection law against a "research grade" GLP-1 seller (2025), which is the template other states can copy. The Bureau's vendor scorecard notes which vendors publish batch testing; none of the scored vendors appears in the tracker as of September 2026.

GLP-1 drugs by prescription. Yes. Board of Medical Examiners rule ARM 24.156.813 (amended February 2024) holds telemedicine to the in-person standard of care and allows the provider-patient relationship to be established through telemedicine if the standard of care does not require an in-person encounter; the licensee must obtain a medical history sufficient for diagnosis before prescribing. There is no explicit in-person examination mandate or questionnaire ban for non-controlled drugs such as GLP-1s. (law.cornell.edu) The branded pens are the only fully approved route; compounded versions are now on the wrong side of the FDA's shortage rules.

Sports and employment testing are not a Montana law question. Growth hormone secretagogues and GHRH analogues are on the WADA Prohibited List everywhere; a standard workplace panel does not screen for peptides. The national legal guide covers both.

Enforcement in Montana

The Bureau found no Montana-level action against a peptide seller, clinic or compounded-GLP-1 seller between 2023 and September 2026. Federal actions apply regardless of state; the enforcement tracker lists them.

Editor's note. No Montana Board of Pharmacy, Board of Medical Examiners or attorney general statement on compounded GLP-1s or research peptides was found, and Montana is not on the February 2025 multistate letter. Treat the empty board fields as nothing found, not as confirmation that nothing exists.

Frequently asked questions

Is BPC-157 legal in Montana?

Montana has not scheduled BPC-157, so possessing it is not a Montana offence. Federally it is an unapproved new drug: selling it for human use is a violation by the seller, and licensed pharmacies cannot compound it because it is not on the 503A bulks list, despite the advisory committee's July 2026 recommendation. Research vendors sell it under a research-use-only label, which the FDA's 2026 letters treat as no defence when the site shows human use.

Can I get semaglutide or tirzepatide by telehealth in Montana?

Yes. Board of Medical Examiners rule ARM 24.156.813 (amended February 2024) holds telemedicine to the in-person standard of care and allows the provider-patient relationship to be established through telemedicine if the standard of care does not require an in-person encounter; the licensee must obtain a medical history sufficient for diagnosis before prescribing. There is no explicit in-person examination mandate or questionnaire ban for non-controlled drugs such as GLP-1s. Compounded versions are no longer covered by the FDA's shortage exception, and the FDA has proposed keeping semaglutide and tirzepatide off the 503B bulks list, so expect availability of compounded product to keep shrinking.

Is HGH legal in Montana?

Only with a valid prescription for an approved use. Montana does not schedule it separately, but federal law, 21 U.S.C. section 333(e), makes distribution or possession for any non-approved use a federal offence. Sermorelin, ipamorelin and CJC-1295 are not HGH and fall under the general unapproved-drug rules instead.

Sources

• https://mca.legmt.gov/bills/mca/title_0500/chapter_0320/parts_index.html
• https://mca.legmt.gov/bills/mca/title_0500/chapter_0320/part_0020/section_0260/0500-0320-0020-0260.html
• https://www.law.cornell.edu/regulations/montana/Mont-Admin-r-24.156.813
• https://mca.legmt.gov/bills/mca/title_0450/chapter_0090/part_0010/section_0020/0450-0090-0010-0020.html

Every Montana fact above was checked against the linked source on 28 September 2026. If a statute or board position has changed, email [email protected] with the link and the page will be corrected and dated.